Planchard D, Olaussen K-A, Soria J-C
Unité Inserm U981, institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.
Rev Mal Respir. 2010 Apr;27(4):387-94. doi: 10.1016/j.rmr.2010.03.003. Epub 2010 Mar 25.
ERCC1 plays a critical role in the repair of lesions in DNA induced by cisplatin. It has been demonstrated that, in patients with resected NSCLC, those with ERCC1-negative tumours had greater benefit from adjuvant chemotherapy than patients with ERCC1-positive tumours. On the other hand, patients with ERCC1-positive tumours have a better prognosis. ERCC1 can be evaluated either by the level of protein expression on immunohistochemical analysis or by quantification of its mRNA expression. At present ERCC1 appears to be a promising biomarker for predicting the benefit of cisplatin based chemotherapy and its modulation could allow sensitisation of tumour cells to this drug. Its use in daily clinical practice requires a further stage of prospective validation studies which are already in progress in patients both with completely resected NSCL or metastatic disease.
ERCC1在顺铂诱导的DNA损伤修复中起关键作用。已经证明，在接受手术切除的非小细胞肺癌患者中，ERCC1阴性肿瘤患者比ERCC1阳性肿瘤患者从辅助化疗中获益更大。另一方面，ERCC1阳性肿瘤患者预后较好。ERCC1可以通过免疫组织化学分析中的蛋白表达水平或其mRNA表达定量来评估。目前，ERCC1似乎是预测基于顺铂化疗获益的一个有前景的生物标志物，对其进行调节可使肿瘤细胞对这种药物敏感。在日常临床实践中使用它需要进一步的前瞻性验证研究阶段，目前针对完全切除的非小细胞肺癌或转移性疾病患者的此类研究正在进行中。
